Globeflex Capital L P Grows Stake in IQVIA Holdings Inc. (NYSE:IQV)

Globeflex Capital L P boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,357 shares of the medical research company’s stock after purchasing an additional 795 shares during the quarter. Globeflex Capital L P’s holdings in IQVIA were worth $4,786,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Smith Group Asset Management LLC purchased a new position in IQVIA during the 4th quarter worth $1,616,000. Simplify Asset Management Inc. increased its holdings in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the period. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new position in shares of IQVIA in the 4th quarter valued at $941,000. Finally, Fifth Third Bancorp increased its holdings in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday. Bank of America lowered their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Morgan Stanley lifted their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Price Performance

Shares of IQVIA stock opened at $185.40 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.34. The business has a 50-day moving average price of $196.63 and a 200 day moving average price of $210.95. The firm has a market cap of $32.69 billion, a PE ratio of 24.72, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.